RCSA
ESPR

REYL & Cie S.A.’s Esperion Therapeutics ESPR Stock Holding History

REYL & Cie S.A.’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.8K Buy
+8,300
New +$23.2K 0.03% 133

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

REYL & Cie S.A.'s ESPR Position: Q2 2026 in Review

REYL & Cie S.A. opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 8,300 shares worth $22.8K. The stake represents 0.03% of the portfolio and ranks #133 among its holdings.

192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • REYL & Cie S.A. held 8,300 shares of Esperion Therapeutics worth $22.8K as of Q2 2026.
  • Esperion Therapeutics was a new REYL & Cie S.A. position in Q2 2026.
  • Esperion Therapeutics made up 0.03% of REYL & Cie S.A.'s portfolio in Q2 2026, its #133 holding.
  • 192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on REYL & Cie S.A.'s 13F filing for Q2 2026, filed 2 Oct 2026.